These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29067662)

  • 1. Identification of Splicing Factors Involved in DMD Exon Skipping Events Using an In Vitro RNA Binding Assay.
    Miro J; Bourgeois CF; Claustres M; Koenig M; Tuffery-Giraud S
    Methods Mol Biol; 2018; 1687():157-169. PubMed ID: 29067662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
    Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
    Niks EH; Aartsma-Rus A
    Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.
    Arechavala-Gomeza V; Anthony K; Morgan J; Muntoni F
    Curr Gene Ther; 2012 Jun; 12(3):152-60. PubMed ID: 22533380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
    Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
    Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y; Yagi M; Matsuo M
    Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon-skipping events in candidates for clinical trials of morpholino.
    Nakano S; Ozasa S; Yoshioka K; Fujii I; Mitsui K; Nomura K; Kosuge H; Endo F; Matsukura M; Kimura S
    Pediatr Int; 2011 Aug; 53(4):524-9. PubMed ID: 21342350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skipping of an exon with a nonsense mutation in the DMD gene is induced by the conversion of a splicing enhancer to a splicing silencer.
    Zhu Y; Deng H; Chen X; Li H; Yang C; Li S; Pan X; Tian S; Feng S; Tan X; Matsuo M; Zhang Z
    Hum Genet; 2019 Jul; 138(7):771-785. PubMed ID: 31168774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.
    Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM
    J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ; Graham IR; Malerba A; Dickson G
    Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
    Aartsma-Rus A; van Ommen GJ
    RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
    Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
    PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.